Cargando…

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis

OBJECTIVES: To compare outcomes of targeted treatment aimed at either low disease activity or remission in patients with early active rheumatoid arthritis (RA). METHODS: Five-year outcomes were compared in 133 patients with early active RA (1987), starting with methotrexate, sulfasalazine and tapere...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akdemir, Gülşah, Markusse, Iris M, Bergstra, Sytske Anne, Goekoop, Robbert J, Molenaar, Esmeralda T, van Groenendael, Johannes H L M, Kerstens, Pit J S M, Lems, Willem F, Huizinga, Tom W J, Allaart, Cornelia F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976116/ https://www.ncbi.nlm.nih.gov/pubmed/29862045 http://dx.doi.org/10.1136/rmdopen-2018-000649

Ejemplares similares

Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
por: Bergstra, Sytske Anne, et al.
Publicado: (2020)

Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial
por: van der Pol, Joy Ardjuna, et al.
Publicado: (2023)

Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial
por: Akdemir, G, et al.
Publicado: (2016)

Age affects joint space narrowing in patients with early active rheumatoid arthritis
por: Matthijssen, X M E, et al.
Publicado: (2016)

Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment
por: Heckert, Sascha L, et al.
Publicado: (2023)

Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry
por: Bergstra, Sytske Anne, et al.
Publicado: (2019)

Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis
por: van Ouwerkerk, Lotte, et al.
Publicado: (2023)

Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry
por: Bergstra, Sytske Anne, et al.
Publicado: (2020)

Evaluation of the joint distribution at disease presentation of patients with rheumatoid arthritis: a large study across continents
por: Bergstra, Sytske Anne, et al.
Publicado: (2017)

DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable
por: Fleischmann, Roy M, et al.
Publicado: (2017)

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial
por: ter Wee, Marieke M, et al.
Publicado: (2017)

Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)
por: Heimans, Lotte, et al.
Publicado: (2016)

Rheumatologists’ adherence to a disease activity score steered treatment protocol in early arthritis patients is less if the target is remission
por: Akdemir, G., et al.
Publicado: (2016)

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study
por: Jansen, Diahann T S L, et al.
Publicado: (2018)

Erosions in the foot at baseline are predictive of orthopaedic shoe use after 10 years of treat to target therapy in patients with recent onset rheumatoid arthritis
por: Bergstra, Sytske Anne, et al.
Publicado: (2015)

Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial
por: Güler-Yüksel, Melek, et al.
Publicado: (2023)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data
Publicado: (2018)

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Reexamining remission definitions in rheumatoid arthritis: considering the twenty-eight–joint Disease Activity Score, C-reactive protein level and patient global assessment
por: Felson, David, et al.
Publicado: (2021)

Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis
por: Amkreutz, Josephine A. M. P., et al.
Publicado: (2021)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis
por: Scott, I C, et al.
Publicado: (2016)

Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis
por: Accortt, Neil A., et al.
Publicado: (2018)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

IgG Anti–Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Cross‐Sectional Study Encompassing ~1,500 Samples
por: Kissel, Theresa, et al.
Publicado: (2022)

Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study
por: Akdemir, Gülşah, et al.
Publicado: (2016)

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial
por: Boers, Maarten, et al.
Publicado: (2022)

Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity
por: Curtis, Jeffrey R, et al.
Publicado: (2012)

Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage
por: Gallo, G, et al.
Publicado: (2016)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study
por: Kubo, Satoshi, et al.
Publicado: (2023)

Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study
por: van Steenbergen, Hanna W, et al.
Publicado: (2015)

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2016)

Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
por: Emery, Paul, et al.
Publicado: (2020)

Serum calprotectin levels do not predict subsequent relapse in rheumatoid arthritis in remission: a post-hoc analysis of STRASS study
por: Romand, Xavier, et al.
Publicado: (2023)

Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift
por: Chatzidionysiou, Katerina, et al.
Publicado: (2019)

ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI)
por: Pope, Janet E, et al.
Publicado: (2018)

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
por: Paulshus Sundlisæter, Nina, et al.
Publicado: (2022)

Role of Anti–Carbamylated Protein Antibodies Compared to Anti–Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First‐Degree Relatives, and Healthy Controls
por: Koppejan, H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ru9mnqsq2iofmbt9m1mgijh61p